Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 November 2019 | Story Charlene Stanley | Photo Supplied
DIABETES read more
The modern clinical research facilities at FARMOVS where the two ground breaking diabetes studies will be conducted.

Diabetes is no longer seen simply as a disease, but as a worldwide epidemic, with alarming increases recorded in both developed and developing countries over the past few years.

About 3,5 million South Africans have diabetes, and many more are unaware that they have it. 

The FARMOVS clinical research facility on the Bloemfontein Campus of the University of the Free State is currently involved in two exciting research studies that could lead to the development of medication for diabetes sufferers burdened by some of its most common complications.

Diabetes in a nutshell

Diabetes is a group of diseases where the sugar (glucose) levels in the blood are too high. 

In diabetes mellitus (DM), the high blood-sugar levels are caused by the body not being able to control the blood-sugar levels properly, because of the body’s inability to produce or use insulin. Insulin is a hormone produced by the pancreas and lowers the blood-sugar levels by helping to move the sugar from the blood into the body cells where the sugar is used as a source of energy.

Type 1 DM is often diagnosed in children or teenagers and occurs when the pancreas does not produce any insulin. Type 2 DM occurs when the pancreas does not make enough insulin, or if the body can no longer use the insulin properly; this is often associated with poor lifestyle choices. Where this type of diabetes used to develop primarily in adults of 40 years and older, it is nowadays not uncommon for children to be diagnosed with it.


It is essential that people who are displaying one or more of the risk factors go for screening. This includes a search Physician at FARMOVS. “If DM is detected early enough, up to 90% of people don’t have to use medication but can address it through changes to their diet and exercise programmes.”

High blood-sugar levels essentially damage the blood vessels, which can lead to long-term implications for a person’s heart, kidneys, eyes, and blood circulation. 
The international studies that FARMOVS forms part of, aim to develop treatments for two of the most common secondary conditions that develop as a result of diabetes. 

Diabetic gastroparesis study

A sufferer’s intestines often don’t function properly due to the damage diabetes causes to the nerves which helps the stomach to empty properly; a condition called gastroparesis. Alleviating this condition, typically marked by abdominal pain, bloating, nausea, vomiting, and early satiety (feeling full after eating only a small amount of food), is the aim of one of the studies.

Diabetic impaired kidney function study

A second research study focuses on developing medication that will have a protective effect on a diabetic’s kidneys.  Although nothing can be done to reverse kidney damage, it is hoped that the treatment will slow down kidney degradation.

Focus on prevention

“Both of these studies are aimed at giving diabetics an increased quality of life, and by no means constitute a cure for their condition,” says Dr Van Jaarsveld.
 “The solution lies in combining the correct and committed use of medication with a decreased calorie intake and an increase in exercise – even if it’s just 30 minutes three times a week.”

Value of educating sufferers

A major benefit for participants in the FARMOVS diabetes research trials, is that they gain valuable insight in their own condition.
Diabetes has been called the ‘silent disease’, since sufferers initially have no symptoms.  For that reason, when the average patient is diagnosed with the disease, he/she already has had it for 10 years.   

For me, diabetes is such a sad disease – especially when you see patients with amputated body parts, knowing that it could have been prevented. It is really up to each individual to take responsibility for their own health,” Dr Van Jaarsveld concludes.

Diabetics who are interested in becoming part of the research studies can register online at www.farmovs.com, or contact FARMOVS at +27 51 410 3111.

News Archive

Award-winning artist Mohau Modisakeng exhibits at UFS
2017-03-02

Description: Mohau Modisakeng exhibition 2 Tags: Mohau Modisakeng exhibition 2

One of the artworks from Modisakeng’s Lefa La Ntate
collection.
Photo: Supplied

Standard Bank Young Artist, Mohau Modisakeng is a multidisciplinary artist who uses memory as a portal linking the past and present to explore themes within the post-apartheid context.

The University of the Free State (UFS) is hosting the Visual Arts 2016 artist’s exhibition, entitled Lefa La Ntate. The exhibition is on at the Johannes Stegmann Art Gallery in the Sasol Library on the Bloemfontein Campus and will run until 31 March 2017.

Artist uses his body to explore influences
Lefa La Ntate represents an emotional moment of grieving and is a critical response to the historical legacy of exploitation and the current lived experience of many black South Africans.  

Modisakeng, who was born in Soweto in 1986, uses his body to explore the influence of South Africa’s violent history on how we understand our cultural, political, and social roles as human beings. “My work responds to the history of the black body within the (South) African context, which is intertwined with the violence of the apartheid era and the early 1990s.”

Acknowledging upcoming young artists
The Young Artist Awards were established to acknowledge emerging young South African artists who have displayed outstanding talent in their artistic endeavours.

The exhibition premiered at the National Arts Festival in Grahamstown in 2016 and has travelled to Port Elizabeth, Pietermaritzburg, and Cape Town.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept